Kelly Holman

Adapsyn Bioscience is a owner and operator of a biotechnology company intended to focus on the identification and characterization of microorganism-derived small molecules, to uncover chemical agents possessing novel biological activities relevant to the biotechnology and pharmaceutical sectors. The company's services is supported bycutting-edge bioinformatic software platforms and state of the art laboratory facilities, enabling researchers to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better protect users from a wide spectrum of diseases.